
Full text loading...
The global rise in antibiotic resistance among pathogenic bacteria poses a critical threat to public health. Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen, displays both intrinsic and acquired resistance mechanisms. Emerging evidence implicates post-transcriptional tRNA modifications in antibiotic resistance, positioning tRNA-modifying enzymes like trmA as potential therapeutic targets.
This study aims to identify potential inhibitors of trmA to disrupt essential cellular pro- cesses and counter antibiotic resistance.
We employed a structure-based virtual screening strategy to identify compounds structurally analogous to S-adenosylmethionine, a universal methyl group donor and known trmA binder. Top-ranked compounds were further evaluated through molecular dynamics (MD) simulations to examine binding-induced conformational dynamics and stability.
Compound 24762163 emerged as a lead candidate with favorable binding affinity and structural compatibility, as confirmed through docking and MD simulations. The compound formed stable interactions with the active site of trmA, indicating its inhibitory potential.
The computational findings suggest that compound 24762163 may effectively disrupt trmA function, thereby impairing tRNA methylation and hindering protein synthesis in P. aeruginosa. Given the essential role of tRNA modifications in bacterial survival and resistance, targeting trmA represents a promising strategy for novel antimicrobial development.
This study identifies compound 24762163 as a promising trmA inhibitor and a potential therapeutic agent to counter antibiotic resistance in Pseudomonas aeruginosa. Targeting tRNA-modifying methyltransferases may offer a novel approach in the fight against drug-resistant pathogens.